AR and Familial prostate cancer: Androgen receptor for dihydrotestosterone (AR), which was downregulated in our series (−15.7-fold, p=2.94e-5), is a steroid hormone nuclear receptor and is a target in prostate cancer treatment by androgen deprivation.